

Applicant Last Name:
Project Title:
Date of Submission:
Section 1: Contact Information
Provide contact information for the principal investigator (PI) of this application. If the PI has designated a representative to submit the proposal on their behalf, please enter the designee's contact information as well.
1. Project Title:
2. Is this a resubmission of a proposal for a project for which support was previously sought under Catalyze? Yes No
Principal Investigator (Last Name, First Name):
4. Organization:
5. Title:
6. Department (or Discipline):
7. Street Address:
8. City:
9. State:
10. Zip code:
11. PI email address:
12. PI telephone number:
13. Name and contact information for corresponding organizational representative, if not the PI:
14. How did you learn about Catalyze? (Select all that apply):
□ NIH/NHLBI website □ My technology transfer office □ NHLBI Catalyze website □ Scientific conference or news □ NIH Translational Program(s) (e.g., REACH, NCAI, SMARTT, CADET II) □ NIH Program Officer □ Catalyze event □ Other (Please specify):
My institution/department

1

Confidential

Investigator: _____



Section 2: PI Demographic Profile Your responses to the following questions allow the Catalyze Coordinating Center to better understand the demographic profile of investigators interested in Catalyze award programs. Your responses to these questions have no influence on proposal selection and will not be shared with reviewers. 15. Position or title: 16. Terminal Degree: 17. Year of Terminal Degree (or Expected Completion Year): 18. Race: What is your race? Please select all that apply American Indian or Alaska Native White Asian Other Black or African American Prefer not to say Native Hawaiian or Other Pacific Islander 19. Ethnicity: Do you describe yourself as Hispanic or Latino? Hispanic or Latino (A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race) Not Hispanic or Latino Prefer not to say 20. Disability Status: Are you disabled? Disabled Not disabled Prefer not to say 21. Has your professional experience to-date been characterized by any of the following? Select all that apply: Been granted a copyright, patent, or trademark A patent has been issued Licensed your technology to another party Applied for funding from a translational research, proof-of-concept, or commercialization support program—other than Catalyze Received funding from a translational research, proof-of-concept, or commercialization

Confidential 2 Investigator: _____

support program—other than Catalyze

Founded a start-up company



ction 3: Technology Profile wide the following information about the project for which Catalyze assistance is sought.				
	Other? If yes, please describe:		Yes/No	
25. W	/hat is the specific technology or product (50-wo	ord limit)?		
	/hat is the indication (50-word limit)?			
27. If	the project is for a therapeutic, what is the targo lechanism of Action) for the product (50-word line	et (e.g., Kinase, Receptor,		

3

Confidential

Investigator: _____



28. In two or three sentences, what is the technical goal of the project (50-word limit)?
29. Indicate the status of intellectual property protection for this technology
 No invention disclosure filed with technology transfer office (or equivalent) Invention disclosure filed with TTO (or equivalent) A patent application has been submitted A trademark has been registered A copyright has been granted Patent has been issued
For devices (including in vitro diagnostics) and combination products:
Does your device incorporate intellectual property (IP) from another component? Yes No Not Applicable
If yes, do you have the necessary rights or freedom to operate? Please explain.
30. Do you have efficacy data in a relevant animal model by the route of administration to be used in the clinic? Please describe relevant efficacy data in the Project Description below.
Yes No Not Applicable Other (please specify)
31. For device and diagnostics, have you confirmed conceptualization and proof of concept via prototyping of all or part of the conceived product with supporting data (i.e., animal or known-sample studies) and documentation? Has a Design History File been created?
Yes No Not Applicable Other (please specify)
32. Project Description . In 1,000 words or less, please provide an overall description of your project. Include the project purpose or objective, therapeutic relevance to the NHLBI mission, a description of preliminary studies, a concise description of the studies you are proposing, the unmet market need or innovation to potentially change standard of care, and commercialization path.
33. Explain why support for this project is sought from NHLBI and the Catalyze program as opposed to private sector or other sources of support.

Confidential 4 Investigator: _____



Section 4: Prior Technology Development Support

The following questions request information about the funding and translational program support history for the technology to be developed under the proposed project. Please provide information about NIH and non-NIH support. Please also indicate whether the principal investigator and/or the technology have been supported by any NIH translational programs.

34. Were any earlier translational or product development stages supported by any of the following NIH-sponsored translational programs? (select all that apply):
☐ NCAI (B-BIC, UC CAI, or NCAI-CC)
REACH 2015 (UofL ExCITE, MN-REACH, or LIBH)
REACH 2019 (KYNETIC, MBArC, ROI, CO-SPARK, or WE-REACH)
NIGMS STTR Tech Transfer Hubs (ASCEND, DRIVEN, SHARP Hub, Southeast Xlerator Network)
☐ tPPG
☐ POCTRN (CAPCat)
☐ VITA
☐ CADET II
Excellence in Hemoglobinopathies
☐ Molecular Imaging of the Lung
☐ Thrombotic and Hemostatic Centers
Pulmonary Vascular-RV Axis
☐ Preclinical GTRP
☐ Preclinical PACT
Preclinical SMARTT
☐ Transformative Platforms
☐ Bioengineering for HLBS
☐ Large Animal Blood Disease Core
☐ None of the above
Other (Please provide name of NIH opportunity or program):

Confidential 5 Investigator: _____